Contemporary surgical management of pediatric non-rhabdomyosarcoma soft tissue sarcoma.
Stephanie F PolitesDaniel S RheeGuido SeitzDall' Igna PatriziaOdion BinitieThomas ScharschmidtTimothy B LautzRoshni DasguptaPublished in: Pediatric blood & cancer (2024)
Non-rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high-risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.
Keyphrases
- sentinel lymph node
- lymph node
- locally advanced
- rectal cancer
- squamous cell carcinoma
- small cell lung cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- neoadjuvant chemotherapy
- newly diagnosed
- clear cell
- type diabetes
- metabolic syndrome
- peritoneal dialysis
- skeletal muscle
- weight loss
- replacement therapy